A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
Study sponsor: Lipocine Inc. · LPCN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-12-18Actual
Enrollment · participants30Actual
Source updated2024-03-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.